Mortality of bullous pemphigoid: An evaluation of 223 patients and comparison with the mortality in the general population in the United States

Journal of the American Academy of Dermatology

Volumn 59, Issue 4, 2008, Pages 582-588

  Parker, Sareeta R S ^a,b   Dyson, Senait ^e   Brisman, Stacey ^a   Pennie, Michelle ^a   Swerlick, Robert A ^a,c   Khan, Rizwana ^d   Manos, Sue ^a   Korman, Benjamin D ^e   Xia, Zongqi ^e   Korman, Neil J ^e  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GRADY MEMORIAL HOSPITAL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; DAPSONE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; PREDNISONE; TETRACYCLINE;

ADULT; AGED; ARTICLE; BULLOUS PEMPHIGOID; CLINICAL EVALUATION; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DATA BASE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; INFORMATION PROCESSING; LABORATORY; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN; UNITED STATES;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CAUSE OF DEATH; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; HUMANS; MALE; MIDDLE AGED; PEMPHIGOID, BULLOUS; RETROSPECTIVE STUDIES; SEX DISTRIBUTION; SURVIVAL RATE; UNITED STATES;

EID: 51349106166     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.07.022     Document Type: Article

References (22)

1. Bernard P., Vaillant L., Labeille B., Bedane C., Arbeille B., Denoeux J.P., et al. Incidence and distribution of subepidermal bullous skin diseases in three French regions. Arch Dermatol 131 (1995) 48-52
2. Meuller S., Klaus-Kovtun V., and Stanley J.R. A 230-kD basic protein is the major bullous pemphigoid antigen. J Invest Dermatol 92 (1989) 33-38
3. Lever W.F. Pemphigus. Medicine (Baltimore) 32 (1953) 1-123
4. Ahmed A.R., Maize J.C., and Provost T.T. Bullous pemphigoid: clinical and immunologic follow-up after successful therapy. Arch Dermatol 113 (1977) 1043-1046
5. Colbert R., Allen D., Eastwood D., and Fairley J. Mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol 122 (2004) 1091-1095
6. Fivenson D.P., Breneman D.L., Rosen G.B., Hersh C.S., Cardone S., and Mutasim D. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 130 (1994) 753-758
7. Bernard P., Bedane C., and Bonnetblanc J.M. Anti-BP 180 autoantibodies as a marker of poor prognosis in bullous pemphigoid: a cohort analysis of 94 elderly patients. Br J Dermatol 136 (1997) 694-698
8. Garcia-Doval I., and Conde Taboada A. Cruces Prado MJ. Sepsis associated with dermatologic hospitalization is not the cause of high mortality of bullous pemphigoid in Europe. J Invest Dermatol 124 (2005) 666-667
9. Gudi V.S., White M.I., Cruickshank N., Herriot R., Edwards S.L., Nimmo F., et al. Annual incidence of mortality of bullous pemphigoid in the Grampian Region of North-east Scotland. Br J Dermatol 153 (2005) 424-427
10. Joly P., Benichou J., Lok C., Hellot M.F., Saiag P., Tancrede-Bohin E., et al. Prediction of survival for patients with bullous pemphigoid. Arch Dermatol 141 (2005) 691-698
11. Roujeau J.C., Lok C., Bastuji-Garin S., Mhalla S., Enginger V., and Bernard P. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol 134 (1998) 465-469
12. Rzany B., Partscht K., Jung M., Kippes W., Mecking D., Baima B., et al. Risk factors for lethal outcome in patients with bullous pemphigoid. Arch Dermatol 138 (2002) 903-908
13. Venning V.A., and Wojnarowska F. Lack of predictive factors for the clinical course of bullous pemphigoid. J Am Acad Dermatol 26 (1992) 585-589
14. Joly P., Roujeau J.C., Benichou J., Picard C., Dreno B., Delaporte E., et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 346 (2002) 321-327
15. In: Beutner E., Chorzelsky T.T., and Kumar V. (Eds). Immunopathology of the skin. 3rd ed. (1987), John Wiley and Sons, New York 4-7
16. Arias E. US life tables, 2001. National vital statistics report;52:14. Hyattsville, MD: National Center for Health Statistics. 2004.
17. Bailar III J.C., and Ederer F. Significance factors for the ratio of a Poisson variable to its expectation. Biometrics 20 (1964) 639-643
18. Bystryn J.-C., and Rudolph J. Why is the mortality of bullous pemphigoid greater in Europe than in the US?. J Invest Dermatol 124 (2005) xx-xxi
19. Bernard P., Enginger V., Venot J., Bedane C., and Bonnetblanc J.M. Pronostic vital de la pemphigoide: analyse d'une cohorte de 78 patients. Ann Dermatol Venereol 122 (1995) 751-757
20. Khumalo N., Kirtschig G., Middleton P., Hollis S., Wojnarowska F., and Murrell D.F. Interventions for bullous pemphigoid. Cochrane Database of Syst Rev 3 (2005) CD002292
21. Korman N. Bullous pemphigoid: the latest in diagnosis, prognosis and therapy. Arch Dermatol 134 (1998) 1137-1141
22. Swerlick R.A., and Korman N.J. Bullous pemphigoid: what is the prognosis?. J Invest Dermatol 122 (2004) xvii-xviii